Merck's New Filing For Keytruda Is A Meaningful Move

Most of the cancer research, at least in terms of dollars, appears to be focused on this area. Merck's Keytruda was previously approved for melanoma but, earlier this month, the FDA granted priority review for the drug for non-small cell lung cancer. This means that in the next 8-10 months, Keytruda can significantly expand its target market. The commercial opportunity can increase significantly due to larger population of potential patients. Lung cancer is one of the most prevalent cancer types...